On October 27, 2023 Sairopa B.V., a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system, reported its poster presentation at the SITC (Free SITC Whitepaper) 38th Annual Meeting taking place November 3-5, 2023 in San Diego, California (Press release, Sairopa, OCT 27, 2023, View Source [SID1234636413]). The presentation, taking the form of a poster, presents early clinical data with encouraging early safety signals on ADU-1604, Sairopa’s anti-CTLA-4 antibody. ADU-1604 is being studied in Phase 1 clinical trials in PD-1 relapse/refractory melanoma patients. Data obtained from the dose-escalation stage will be presented and will provide further specifics about the safety, efficacy of ADU-1604, as well as modulation of pharmacodynamic markers supporting its potential use in future clinical applications. sairopa.com
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster information:
Title: ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients
Date: Saturday, November 4
Poster Hall Hours: 9:00 a.m. – 8:30 p.m. (Reception: 5:10 p.m. – 6:40 p.m.)
Onsite Location: Exhibit Halls A and B1 – San Diego Convention Center
Number: 770